Last reviewed · How we verify
Discontinuation antipsychotic treatment — Competitive Intelligence Brief
phase 3
Psychiatry
Small molecule
Live · refreshed every 30 min
Target snapshot
Discontinuation antipsychotic treatment (Discontinuation antipsychotic treatment) — Fundación Pública Andaluza Progreso y Salud. This is a clinical trial protocol studying the effects of discontinuing antipsychotic medication in patients currently treated with antipsychotics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Discontinuation antipsychotic treatment TARGET | Discontinuation antipsychotic treatment | Fundación Pública Andaluza Progreso y Salud | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Discontinuation antipsychotic treatment CI watch — RSS
- Discontinuation antipsychotic treatment CI watch — Atom
- Discontinuation antipsychotic treatment CI watch — JSON
- Discontinuation antipsychotic treatment alone — RSS
Cite this brief
Drug Landscape (2026). Discontinuation antipsychotic treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/discontinuation-antipsychotic-treatment. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab